Novartis files ceritinib as data show selectivity bonus
This article was originally published in Scrip
Executive Summary
Clinical data supporting a US approval application for Novartis's novel ALK inhibitor ceritinib (LDK378) suggest that it is effective in most patients who become resistant to Pfizer's first-in-class product Xalkori (crizotinib), with a reassuring safety profile.